FindTrial
Sign In

GT801 Injection

BIOLOGICAL3 trials

Sponsors

Grit Biotechnology, Vivacta Biotechnology (Shanghai) Co., Ltd.

Conditions

Autoimmune Hemolytic Anemia (AIHA)B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin's Lymphoma (B-NHL)Chronic Lymphocytic Leukemia (CLL)Moderate to Severe Refractory Autoimmune DiseaseModerate to Severe Refractory Autoimmune Diseases

Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
RecruitingNCT07205315
Grit BiotechnologyAutoimmune Hemolytic Anemia (AIHA), B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Non-Hodgkin's Lymphoma (B-NHL) +1
Start: 2025-09-26End: 2028-08-31Target: 28Updated: 2026-07-20
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
RecruitingNCT07333118
Grit BiotechnologyModerate to Severe Refractory Autoimmune Disease
Start: 2025-11-07End: 2028-03-31Target: 22Updated: 2026-05-27
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases
RecruitingNCT07614191
Vivacta Biotechnology (Shanghai) Co., Ltd.Moderate to Severe Refractory Autoimmune Diseases
Start: 2026-05-25End: 2031-12-30Target: 22Updated: 2026-06-02

Related Papers

First-in-human study of in vivo CAR-T therapy GT801 in adults with relapsed or refractory CD19-positive B-cell hematologic malignancies.
Journal of Clinical Oncology2026-05-27